47 Avenue Road
90 articles with Portage Biotech
Portage Raises More Than US$6.7 Million Through Non-Brokered Private Placement; Temporary Symbol Change on OTC Markets
TORONTO, June 16, 2020 /PRNewswire/ - Portage Biotech Inc. is very pleased to announce that, further to its news release dated May 25, 2020, it has closed a non-brokered private placement for gross proceeds of US$6,788,600 through the issuance of 678,860 common shares at a price of US$10.00 per Common Share.
Portage Biotech Inc. (CSE: PBT.U) (OTC-Markets: PTGEF) ("Portage" or the "Corporation") wishes to announce that, further to its news release dated May 25, 2020 , the Corporation's common shares will commence trading on a one hundred (100) old for one (1) new share consolidated basis (the "Consolidation") (also kn
Supports advancement of its immune-oncology programs Enables portfolio expansion/product acquisitions Intention to proceed with consolidation (reverse stock split)
Portage Biotech Inc. a leader in the early stage immune oncology space announced the appointment of Allan L. Shaw to Chief Financial Officer at the Portage level and will assist in its portfolio companies as well.
TORONTO, May 11, 2020 /PRNewswire/ - Portage Biotech Inc., is pleased to announce that it has made an additional €900k investment in its associate, Stimunity, the Paris-based cancer immunotherapy company focused on STING.
Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update on a subsidiary company, Saugatuck Therapeutics Ltd. ("Saugatuck"). Portage Biotech Inc. holds an 70% equity interest in Saugatuck. Portage is pleased to announce that initial proof of concept of the n
Portage Biotech Inc. wishes to announce that effective April 15, 2020, the Ontario Securities Commission revoked its Failure-to-File Cease Trade Order issued against the Company on August 2, 2019 and that trading of the Company's common shares on CSE is expected to resume shortly..
Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update on a portfolio company, Intensity Therapeutics, Inc. ("Intensity"). Portage Biotech Inc. holds an 9.7% equity interest in Intensity. Intensity signs clinical trial collaboration with Bristol Mye
Portage Announces Filing of Financial Statements and Accompanying MD&A and Provides Company Operations Updates
Notable milestones include the acquisition of SalvaRx, appointment of new CEO, Dr. Ian Walters, and the purchase of Intensity Holdings Limited
Company was also deemed to be in default under the rules of the CSE which resulted in the suspension of trading in the Company's shares.
Portage Biotech Inc. is providing the following update on the status of efforts being made to revoke a failure to file cease trade order issued by the Ontario Securities Commission on August 2, 2019 against the securities of the Company.
Portage Biotech Inc. (PBT.U, OTC Markets: PTGEF) ("Portage" or the "Company") is providing an update on the status of the filing of its audited annual financial statements for the year ended March 31, 2019, accompanying management discussion and analysis together with the related certifications (collectively, the "Annual Filings").
Portage Biotech Inc. announced that, further to its news release of July 26, 2019, it will be delayed in filing its audited annual financial statements for the year ended March 31, 2019, the related management's discussion and analysis and certificates of its CEO and CFO with Canadian securities regulators until after deadline.
Portage Biotech Inc., announced that it will likely miss its filing deadline of July 29, 2019 to file its annual financial statements for the fiscal year ended March 31, 2019 and related management discussion and analysis as required by applicable Canadian securities laws.
Portage Announces Increase in Holdings of Portfolio Company, Intensity Therapeutics With Positive Business, Regulatory, & Clinical Updates
Portage Biotech Inc., ("Portage" or the "Company") (CSE: PBT.U, OTC Markets: PTGEF) today announced it has entered in an agreement with Fast Forward Innovations Limited (AIM Market: FFWD) ("Fast Forward") to purchase Intensity Holdings Limited ("IHL"), a wholly-owned subsidiary of fast forward.
The Board of Directors of Portage Biotech Inc announces that Dr. Declan Doogan, the current Chief Executive Officer ("CEO") has decided to step down with immediate effect.
Portage Biotech Inc., is pleased to announce that it has made an additional €600k investment in its associate, Stimunity, the Paris-based cancer immunotherapy company focused on STING.
Portage Biotech Inc. announces that it has changed its auditors from Swartz Lewisky Feldman LLP to Marcum LLP effective immediately.
Portage Biotech Inc. wishes to announce that due to an oversight, closing of the SalvaRx Acquisition was completed prior to obtaining final CSE approval.
FINRA also imposed trading halt on our shares on OTC Market.